(3R)-1-[[4-(trifluoromethoxy)phenyl]methyl]-3-[[3-(trifluoromethyl)phenyl]sulfonylmethyl]pyrrolidine
C20H19F6NO3S — CID 158782417
Data last refreshed: (MolForge compound catalog, from PubChem)
About (3R)-1-[[4-(trifluoromethoxy)phenyl]methyl]-3-[[3-(trifluoromethyl)phenyl]sulfonylmethyl]pyrrolidine
(3R)-1-[[4-(trifluoromethoxy)phenyl]methyl]-3-[[3-(trifluoromethyl)phenyl]sulfonylmethyl]pyrrolidine (PubChem CID 158782417) has the molecular formula C20H19F6NO3S and a molecular weight of 467.43 g/mol. Its IUPAC name is (3R)-1-[[4-(trifluoromethoxy)phenyl]methyl]-3-[[3-(trifluoromethyl)phenyl]sulfonylmethyl]pyrrolidine.
Molecular Properties
| Compound Name | (3R)-1-[[4-(trifluoromethoxy)phenyl]methyl]-3-[[3-(trifluoromethyl)phenyl]sulfonylmethyl]pyrrolidine |
|---|---|
| PubChem CID | 158782417 |
| Molecular Formula | C20H19F6NO3S |
| Molecular Weight | 467.43 g/mol |
| Exact Mass | 467.10 |
| IUPAC Name | (3R)-1-[[4-(trifluoromethoxy)phenyl]methyl]-3-[[3-(trifluoromethyl)phenyl]sulfonylmethyl]pyrrolidine |
| SMILES | O=S(=O)(C[C@@H]1CCN(Cc2ccc(OC(F)(F)F)cc2)C1)c1cccc(C(F)(F)F)c1 |
| InChI | InChI=1S/C20H19F6NO3S/c21-19(22,23)16-2-1-3-18(10-16)31(28,29)13-15-8-9-27(12-15)11-14-4-6-17(7-5-14)30-20(24,25)26/h1-7,10,15H,8-9,11-13H2/t15-/m1/s1 |
| InChIKey | IRFZLNPWZYVGOI-OAHLLOKOSA-N |
| XLogP | 4.90 |
| TPSA | 46.61 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 467.43 |
| LogP ≤ 5 | 4.90 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 158782417 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.